Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(17 sites)

Canada

University of Calgary, Calgary, Alberta

University of British Columbia, Vancouver, British Columbia

Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia

NL Health Services, St. John's, Newfoundland and Labrador

Nova Scotia Health, Halifax, Nova Scotia

Hamilton General Hospital, Hamilton, Ontario

Kingston General Hospital, Kingston, Ontario

London Health Sciences Centre, London, Ontario

Newmarket Electrophysiologist Research Group 'NERG', Newmarket, Ontario

University of Ottawa Heart Institute, Ottawa, Ontario

Heart Health Institute Research Inc, Scarborough Village, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

St. Michael's Hospital, Toronto, Ontario

Montreal Heart Institute, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec

Hopital du Sacré-Coeur de Montréal, Montreal, Quebec

University Institute of Cardiology and Pneumology of Quebec, Québec, Quebec